Articles related to DIABETIC RETINOPATHY

AI-enabled retinal imaging platforms are being deployed across healthcare settings to identify ocular and systemic disease signals, though the role of these technologies continues to evolve alongside regulatory approvals and clinical validation.

A conference presentation at Optometry’s Meeting 2026 examined teleretina adoption in primary care settings and the expanding role of AI-assisted retinal imaging, including autonomous diabetic retinopathy detection and emerging oculomics applications, while cautioning clinicians about AI bias and the limits of consumer-facing large language models.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.

Vitreoretinal surgeons describe off-label fibrin glue application as a localized tamponade alternative for rhegmatogenous retinal detachment repair, hemorrhage control, and retinal edge stabilization in cases where gas or silicone oil poses prohibitive patient or logistical constraints.

A retinal specialist reviewing GLP-1 ocular safety evidence at the Retina World Congress concluded that current data do not support withholding therapy based on ocular risk alone, while recommending baseline retinal examination and closer monitoring in patients with preexisting severe diabetic retinopathy.